Alzheimer´s Disease Clinical Trial
— VogelOfficial title:
Prospective Study to Evaluate the Predictive Value of Vagus Somatosensory Evoked Potentials (VSEP) and Near-infrared Spectroscopy (NIRS) in the Early Diagnosis of Alzheimer´s Disease
NCT number | NCT02224326 |
Other study ID # | Vogel-1 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2011 |
Est. completion date | January 2023 |
Verified date | October 2023 |
Source | University of Wuerzburg |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In its long preclinical course, AD shows a spreading pattern of specific pathology in a uniform sequence of predictable steps including brainstem nuclei in early stages. Many of these nuclei which are early involved in AD take equally part in the afferences of the Xth cranial nerve, the Vagus nerve. A method for the functional assessment of Vagus-related nuclei in the lower brainstem is the technique of somatosensory evoked potentials of the Vagus nerve (VSEP). This method targets the accessibility of early functional changes by evoked potentials on one hand and the early affection of specific brainstem nuclei comprising Vagus afferences in the course of AD on the other hand. The method of VSEP takes advantage of the transcutaneous stimulation of the auricular branch of the Vagus nerve (ABVN) which is presumed to be the only sensory part of this nerve innervating parts of the outer meatus acoustics at the tragus. This cutaneous branch was shown to gain access to Vagus afferences via brainstem regions which are affected in the course of AD. VSEP latencies in AD were shown to be significantly longer as compared to healthy controls. Yet, if VSEP really are suited for the early detection of AD is still not known. Functional near-infrared spectroscopy (fNIRS) measures changes in cerebral oxygenation by means of near-infrared light using wavelengths of 650-850 nm. The principle of fNIRS is based on the principle that regional neuronal activation of the brain leads to an increase in metabolism and oxygenation of brain tissue in that region which is accompanied by an elevated regional cerebral blood flow. In AD, there is a growing body of literature reporting deviant fNIRS activation patterns for a variety of tasks. For example, it was shown that the fNIRS activation pattern in frontal and parietal cortex areas in subjects with AD performing the line orientation paradigm is clearly different from healthy controls. Yet, if fNIRS is suited as a means of early detection of AD is not known. Therefore we aimed at testing the predictive value of VSEP and fNIRS in the early detection of AD. The hypothesis to be tested within this study states that subjects developing AD or MCI within an observation period of 6 years depict longer VSEP latencies, a different fNIRS oxygenation pattern and a lower performance in neuropsychologic rating below the level of dementia at baseline than those who remain cognitively stable.
Status | Completed |
Enrollment | 604 |
Est. completion date | January 2023 |
Est. primary completion date | January 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 70 Years to 78 Years |
Eligibility | Inclusion Criteria: - inhabitant of Wuerzburg - born between 1.4.1936 and 31.3.1941 - able to give informed consent Exclusion Criteria: - manifestation of - apart from dementia - other severe psychiatric disease such as Schizophrenia, neurologic disease such as Parkinson´s disease or stroke or intern disease such as cancer within the past 12 months - severe, uncorrected see or hearing disturbance |
Country | Name | City | State |
---|---|---|---|
Germany | University Clinic Wuerzburg | Wuerzburg |
Lead Sponsor | Collaborator |
---|---|
University of Wuerzburg |
Germany,
Katzorke A, Zeller JBM, Muller LD, Lauer M, Polak T, Deckert J, Herrmann MJ. Decreased hemodynamic response in inferior frontotemporal regions in elderly with mild cognitive impairment. Psychiatry Res Neuroimaging. 2018 Apr 30;274:11-18. doi: 10.1016/j.pscychresns.2018.02.003. Epub 2018 Feb 11. — View Citation
Polak T, Herrmann MJ, Muller LD, Zeller JBM, Katzorke A, Fischer M, Spielmann F, Weinmann E, Hommers L, Lauer M, Fallgatter AJ, Deckert J. Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. J Neural Transm (Vienna). 2017 Nov;124(11):1473-1488. doi: 10.1007/s00702-017-1781-0. Epub 2017 Sep 1. — View Citation
Zeller JBM, Katzorke A, Muller LD, Breunig J, Haeussinger FB, Deckert J, Warrings B, Lauer M, Polak T, Herrmann MJ. Reduced spontaneous low frequency oscillations as measured with functional near-infrared spectroscopy in mild cognitive impairment. Brain Imaging Behav. 2019 Feb;13(1):283-292. doi: 10.1007/s11682-018-9827-y. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Activities of daily living scale | 6 years | ||
Primary | Mini Mental State Examination (MMSE) | 6 years | ||
Secondary | Dementia detection test | 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02245737 -
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
|
Phase 2/Phase 3 | |
Completed |
NCT02360527 -
Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease
|
N/A | |
Completed |
NCT01225809 -
AD01 Follow up Extension Visit
|
N/A | |
Terminated |
NCT01117948 -
Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.
|
Phase 2 | |
Terminated |
NCT01736579 -
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
|
Phase 3 | |
Completed |
NCT02501876 -
Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT01695889 -
Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?
|
N/A | |
Completed |
NCT00608946 -
Treatment With Copper in Patients With Mild Alzheimer´s Dementia
|
Phase 2 | |
Terminated |
NCT02008513 -
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
|
Phase 2 | |
Terminated |
NCT01125683 -
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT01357629 -
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
|
N/A | |
Terminated |
NCT01524887 -
Phase 3 IGIV, 10% in Alzheimer´s Disease
|
Phase 3 | |
Completed |
NCT00692705 -
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
|
Phase 1 | |
Active, not recruiting |
NCT02623764 -
EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors
|
||
Completed |
NCT00948259 -
Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00818662 -
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease
|
Phase 3 |